ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Health Technology

Lupin Ltd.

Company Background

Lupin is a major generic drugmaker that conducts business in more than 100 countries. Among India's five biggest pharmaceuticals, it has about 10 production bases in India and exports generic drugs to other countries.

It was founded in 1968 by Desh Bandhu Gupta, a researcher at a science university. Since the early 2000s, it has been actively buying companies in South Africa, Mexico, even Japan.

It got a head start on its Indian competitors by building a supply network in Japan. It did so in 2007 by acquiring Kyowa Pharmaceutical Industry, an Osaka-based medium-size generic drugmaker. In 2014, it set up a venture with Yoshindo, a generic drug company based in Japan's Toyama Prefecture, to jointly develop generic biomedicines.

Zyma Laboratories, an affiliate company run by Desh Bandhu Gupta and other executives, is Lupin's top shareholder; the founding family still owns some shares in Lupin.

Business Summary

Lupin Ltd. is an innovation led transnational pharmaceutical company, which engages in the manufacture of pharmaceutical products. It offers branded and generic formulations, biotechnology products, and active pharmaceutical ingredients. The firm caters to the cardiovascular, diabetology, asthama, pediatrics, central nervous system, gastro-intestinal, anti-infectives, nonsteroidal anti-inflammatory drug therapy, anti-tuberculosis, and cephalosporins industry segments. It operates through the following geographical segments: India, USA, Japan, and Others. The company was founded by Desh Bandhu Gupta in 1968 and is headquartered in Mumbai, India.

Financial Highlights

Mar 2022 INRUSD
Gross Profit73,081.50M980.83M
Operating income12,860.70M172.60M
Income before tax-13,725.70M-184.21M
Net income-15,280.40M-205.07M
Diluted EPS-33.65-0.45
Dividends Per Share40.05
Total Assets218,212.20M2,879.73M
Total liabilities95,992.40M1,266.80M
Total equity121,268.80M1,600.38M
Operating cash flow2,761.30M37.05M
Currency in INRCurrency in USD

Historical Data

 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 155,509.10M 144,095.60M 151,619.10M 150,249.50M 163,209.80M
Gross Profit 89,416.30M 69,354.60M 71,385.80M 73,314.70M 73,081.50M
Operating income 18,628.40M 15,088.80M 12,171.10M 17,142.80M 12,860.70M
Income before tax 5,432.90M 14,052.10M 7,532.90M 16,751.20M -13,725.70M
Net income 2,512.60M 5,120.90M -3,994.90M 12,165.30M -15,280.40M
EBITDA 59,546.50M 23,549.30M 21,873.30M 25,677M 21,045.70M
Diluted EPS 5.54 13.35 -5.95 26.72 -33.65
Dividends Per Share 5 5 6 6.50 4
Total Assets 263,053.80M 279,493.70M 249,838.50M 236,104.40M 218,212.20M
Total liabilities 126,882.40M 141,602.80M 123,953.10M 97,523.30M 95,992.40M
Total equity 135,761.40M 137,413.10M 125,357.80M 138,022.20M 121,268.80M
Operating cash flow 15,901M 14,897.10M 12,562.80M 17,296.30M 2,761.30M
 Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022
Revenue 2,412.26M 2,060.19M 2,138.31M 2,023.97M 2,190.45M
Gross Profit 1,387.02M 991.59M 1,006.76M 987.60M 980.83M
Operating income 288.96M 215.73M 171.65M 230.92M 172.60M
Income before tax 84.27M 200.90M 106.23M 225.65M -184.21M
Net income 38.97M 73.21M -56.34M 163.87M -205.07M
EBITDA 923.68M 336.69M 308.48M 345.88M 282.45M
Diluted EPS 0.08 0.19 -0.08 0.36 -0.45
Dividends Per Share 0.07 0.07 0.08 0.08 0.05
Total Assets 4,033.22M 4,034.55M 3,302.50M 3,229.27M 2,879.73M
Total liabilities 1,945.40M 2,044.06M 1,638.48M 1,333.85M 1,266.80M
Total equity 2,081.53M 1,983.58M 1,657.04M 1,887.77M 1,600.38M
Operating cash flow 246.65M 212.99M 177.17M 232.99M 37.05M

Valuation Measures

Mar 2022
Operating margin7.87%
Profit margin-9.36%

Key executives

  • Chief Executive Officer & Executive Director: Vinita D. Gupta
  • Global CFO & Executive Director: Ramesh Swaminathan
  • President-Global Quality & Compliance: Johnny Mikell
  • Secretary & Compliance Officer: Rajvardhan V. Satam
  • Managing Director & Executive Director: Nilesh Deshbandhu Gupta


  • Lupin Investments Pvt Ltd. (45.2%)
  • Life Insurance Corporation of India (Investment Portfolio) (8.3%)
  • ICICI Prudential Asset Management Co. Ltd. (5.0%)
  • HDFC Asset Management Co. Ltd. (Invt Mgmt) (4.0%)
  • Nippon Life India Asset Management Ltd. (Invt Mgmt) (1.9%)
  • The Vanguard Group, Inc. (1.6%)
  • Norges Bank Investment Management (1.3%)
  • BlackRock Fund Advisors (1.2%)
  • SBI Funds Management Pvt Ltd. (1.1%)
  • DSP Investment Managers Pvt. Ltd. (1.0%)

Contact Details

  • Website:
  • Address: Kalpataru Inspire, Off Western Expressway Highway, Mumbai, 400055, India
  • Phone: +91.22.66402323

Related Companies

  • Anglo French Drugs & Industries Ltd. /Portfolio of Brands/
  • Lupin Europe GmbH LLC
  • Lupin Japan & Asia Pacific KK
  • Lupin Latam, Inc.
  • Lupin Pharma LLC
  • Medquimica Industria Farmaceutica
  • Lupin Middle East FZ LLC
  • Generic Health Sdn. Bhd.
  • Lupin Philippines, Inc
  • Bellwether Pharma Pty Ltd.
  • Lupin Mexico SA de CV
  • Lupin Pharma Canada Ltd.
  • Lupin Holdings BV
  • Lupin Management, Inc.
  • Lupin Research, Inc.
  • Lupin, Inc.
  • VeeGo Pharma LLC
  • Lupin Atlantis Holdings SA
  • Lupin Farmaceutica Do Brasil Ltda.
  • Lupin Pharmaceuticals Ltd/Brazil/
  • Lupin Employees Benefit Trust
  • Nanomi BV
  • Lupin Healthcare Ltd.
  • Gavis Pharmaceuticals LLC
  • Lupin Chemical (Thailand) Ltd.
  • Lupin Australia Pty Ltd.
  • Lupin Holdings B.V., Netherlands
  • Polynova Industries Ltd.
  • Lupin Laboratories Ltd.
  • Laboratorios Grin SA de CV


  • Dr. Reddy's Laboratories Ltd.
  • Amneal Pharmaceuticals, Inc. Class A
  • Sun Pharmaceutical Industries Limited
  • Amneal Pharmaceuticals, Inc. Class A
  • Innoviva, Inc.
  • Dare Bioscience, Inc.
  • Midatech Pharma Plc
  • Agile Therapeutics, Inc.
  • Bora Pharmaceuticals Co Ltd
Last Updated on 24 Mar, 2023

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more